

Johnson County Educational Research Triangle (JCERT)
January 28, 2013
Minutes

Attendees:

Triangle Authority:

Present: Ed Eilert, Chairman
Mike Boehm, Vice Chairman
Carl Gerlach
C. Edward Peterson
Kay Wolf
Jeff Melcher

Others: Dennis Day - JCCC
Dan Richardson - K-State Olathe
Lindy Eakin - K-State
Maxine Stoltz - KU Med
Terry Calaway - JCCC
Shelly Hammond - Allen, Gibbs & Houlik
Steph Tobis - KUEC
Mary Ryan - KUEC
Diana Marrs - KUEC
James R. Hubbard - HRKK

Introduction of Persons Present	Chairman Eilert took a roll call of the JCERT Authority members and introduced new members of the Board and guests.
Quorum	Mr. Eilert announced that a quorum was present.
Discussion regarding procedure of transfer of funds	The next item of business was discussion regarding the procedure of transfer of funds and the United Missouri Bank accounts.
Minutes	Upon motion, the Minutes of the 10/31/12 JCERT Authority meeting were unanimously approved (w/Jeff Melcher and Kay Wolf abstaining).
Audit Extension Report	Shelly Hammond presented a proposal for an extension of the contract for her firm's services which included a proposed price for a one-year extension or a two-year extension with a discount. After a general discussion and an explanation by Shelly of the services being provided by her firm, motion was made and seconded to extend Allen Gibbs & Houlik for a two-year period, which would include a total price of \$16,950.00 for June 30, 2013 and

	<p>\$17, 150.00 for June 30, 2014. The Agreed Upon Procedures is based on an hourly rate of \$125.00 per hour and an estimated time of 80 hours.</p> <p>Chairman Eilert announced that after the two-year extension, the Authority would consider doing another RFP process to make sure the auditing fees to the Authority were competitive.</p>
Approval of Invoice of Allen, Gibbs & Houlik	The next item of business was the approval of the Invoice submitted by Allen Gibbs & Houlik for the work performed by their firm to date in the amount of \$8,115.20 and upon motion and second, the Invoice was approved.
Approval of Invoice of Hubbard, Ruzicka, Kreamer & Kincaid L.C.	The next item of business was the approval of the Invoice submitted by Hubbard, Ruzicka, Kreamer & Kincaid L.C. in the amount of \$1,425.00. Mr. Hubbard indicated that the Invoice being presented was not itemized and that if the Authority wanted to wait until the next meeting, an itemized bill would be presented at that time. After a general discussion, a motion was made and seconded to approve the Invoice with an itemized billing being presented at the next regular meeting.
University Update KU Clinical Research Center - presented by Maxine Stoltz	See attached
University Update K-State Olathe Campus- Presented by Dr. Dan Richardson	See attached
University Update KU Edwards Campus presented by Mary Ryan	See attached
Next Meeting	The next regular meeting will be held on Tuesday, May 7, 2013 at 7:30 a.m. at the K-State Olathe Campus, Room 120, Executive Boardroom, 22201 Innovation Drive, Olathe, Kansas 66061.

KU CLINICAL RESEARCH CENTER

**University of Kansas Medical Center
JCERTA Year in Review – Jan-Dec 2012
Presented to the JCERTA Board
January 25, 2013**

Purpose of JCERT funding

K.S.A. 19-5005 states that revenues from the tax are to be spent for building construction, academic and research program development and growth, faculty and staff recruitment and retention, and operations and maintenance in support of medical education and life sciences and cancer research programs at the University of Kansas Medical Center's Johnson County locations. The Resolution adopted by the Board further states "The KU Clinical Research Center, which will provide clinical trials for cancer and other diseases, will be located in an existing renovated building of approximately 75,000 square feet. The KU Clinical Research Center will also house KU's clinical research infrastructure, which will support clinical trials designed to translate discoveries made in the laboratory into treatments for patients, as well as conference and administrative support for the Midwest Cancer Alliance Partners Advisory Board."

KU-CRC Building

- The University of Kansas Clinical Research Center (CRC) opened to patients on January 23, 2012. Funds from the Johnson County Education Research Triangle sales tax (JCERT) and revenue bonds supported by the sales tax were used to renovate the facility. Sales tax receipts are now being used to pay debt service and maintain the building, and to pay the costs of the clinical research infrastructure supporting clinical trials designed to translate discoveries made in the laboratory into treatments for patients.
- The total square footage of the building after renovation is 82,400 SF. There is 24,400 SF of clinic space, 8,300 SF of lab space, 20,600 SF of office space, and 29,100 SF of public space including sitting areas and conference rooms. The cost to renovate and equip the facility was approximately \$19.4 million funded with \$14.4 million in bond proceeds and approximately \$5 million in JCERT funds.
- The building is home to Frontiers: The Heartland Institute for Clinical and Translational Research, The Alzheimer's Disease Center, the Clinical and Translational Science Unit (CTSU), the Early Phase Oncology Clinical Research Program, the KU Cancer Center's Clinical Research Office, and the Midwest Cancer Alliance.

The Clinical and Translational Science Unit (CTSU)

- The CTSU consists of the clinic and staff supporting conduct of clinical trials for KUMC researchers outside oncology. Major areas of therapeutic focus are Alzheimer's disease, Lou Gehrig's disease, diabetes, and kidney disease.
- The CTSU is running over 100 clinic trials across a wide variety of therapeutic areas.
- The CTSU has had over 2,200 patient visits since opening in January 2012 and have had 374 new patients accrued to clinical trials.

Month of Visit	Patient Visits	New Patients to CTSU
January 2012	126	25
February 2012	188	42
March 2012	185	34
April 2012	175	29
May 2012	176	29
June 2012	197	48
July 2012	175	31
August 2012	226	42
September 2012	209	11
October 2012	245	37
November 2012	177	26
December 2012	182	20
Total:	2261	374

Visit Demographics	Patient Visits to the CTSU	Percentage
From metro area Kansas	1081	47.8
From metro area Missouri	517	22.9
Outside metro area Kansas	357	15.7
Outside metro area Missouri	203	9.0
Other states 11 visits from Colorado 13 visits from Nebraska 12 visits from Illinois 27 visits from other states*	63	2.8
Outside US 40 visits (3 patients) from New Zealand	40	1.8
Total:	2261	100


*Includes Arkansas, California, Iowa, Michigan, Oklahoma

- The CTSU has hosted around 200 pharmaceutical company visits. Over the first year of operation, they have had over numerous sponsor visits from 18 different companies including BioMarin, GlaxoSmithKline, Amicus, Genzyme, Janssen, Pfizer, Genentech, Otsuka, Wyeth, Novartis, Neuraltis, Cytokinetics, PTC Therapeutics, Eli Lilly, Biogen, Novartis, Medtronic, Merck, and Seaside Therapeutics. Over the last 4 months, these sponsor visits required 27 hotel nights and almost all flew in and out of KCI and either rented cars or used limo services.
- For the **BioMarin** project, a study on a rare neurological disorder called Pompe Disease, 3 patients from **New Zealand** are on trial. They arrived at various between June and July and will stay for various lengths through October 3. They get an infusion every 2 weeks and when not at the CTSU, stay in a local hotel, eat at local restaurants, and shop and site-see locally. For the same project, 1 patient is coming in from **Chicago** every other week from July through December. She flies into KC and eats, shops, and uses local transportation. Another patient on this study has been driving from **St. Louis** every other week starting in January 2012 and will continue on study through January 2013. Again, eating, shopping, and purchasing gas for the trip back home.

Oncology Early Phase Clinical Trials Program

- The Early Phase Oncology Program supports studies on drugs which are being tested for the first time in human beings or are very early in development.
- As of January 15, 2012, the program has 12 active studies (open to enrollment). There are an additional 9 studies in the approval process (scientific and ethics) and 7 studies

that are earlier in the approval process. Six trials have been closed to enrollment since the center opened.



- Patient inquiries regarding participation in or eligibility for oncology clinical trials are being tracked by our Early Phase Nurse Navigator.

Month of Inquiry	Local Inquiries	Out of Town Inquiries	Consented for Study Treatment	Notes
February 2012	7	2	1	2 patients called from Kuwait, 1 came to KU for treatment
March 2012	17	1	2	1 patient placed on study; 1 came to KU for treatment
April 2012	9	3	0	1 called from Nevada; 1 from Pittsburgh (KS); 1 inquiry from India
May 2012	9	1	5	2 patients came to KU for treatment; 3 placed on clinical trial
June 2012	8	3	6	5 evaluated for trials; 1 placed on trial
July 2012	86	25	10	8 consented or on trials currently; 2 opted for other treatment
August 2012	110	56	5	2 consented or on trials currently; 1 considering other options
September 2012	94	26	8	Patient calls from Mayo, MDAnderson, Chicao, Arizona, Tulsa
October 2012	136	63	16	Calls from far reaches of KS & MO, Chicago, Alaska, Nebraska
November 2012	72	37	6	One inquiry from San Diego
December 2012	123	69	14	12 enrolled in study; calls from Armenia, Illinois, Arizona
Total:	671	286	73	

*Outside referrals have come in from MN, MT, IN, TN, TX, IL, NE, and from all across KS and MO.

- Our Nurse Navigator also tracks hits to the KU Cancer Center website. Recent numbers show an upward trend:
 - August 2012 the website had 5,261 entrances with 15,959 page views
 - September 2012 – 6,708 entrances and 19,169 page views
 - October 2012 – 5,710 entrances and 21,163 page views
 - November 2012 – 5,992 entrances and 18,429 page views
- On a month-to-month basis, we count individual patients being treated at the CRC and where they are coming from. Over the last year, the cumulative total of visitors from our primary service area and from outside this area are shown in the following table:

Patients Treated on Clinical Trials: January 2012 - December 2012

Patient Origin

	County State	Unique	% of Total
Inside Primary Service Area	Johnson, KS	93	46.0%
	Jackson, MO	49	24.3%
	Wyandotte, KS	33	16.3%
	Clay, MO	20	9.9%
	Platte, MO	5	2.5%
	Leavenworth, KS	2	1.0%
Inside Primary Service Area Total		202	71.6%
Outside Primary Service Area	Shawnee, KS	8	10.0%
	Cass, MO	8	10.0%
	Douglas, KS	7	8.8%
	Lyon, KS	6	7.5%
	Franklin, KS	4	5.0%
	Lafayette, MO	4	5.0%
	Sedgwick, KS	3	3.8%
	Allen, KS	2	2.5%
	Barton, KS	2	2.5%
	Butler, KS	2	2.5%
	Doniphan, KS	2	2.5%
	Ellis, KS	2	2.5%
	Jefferson, KS	2	2.5%
	McPherson, KS	2	2.5%
	Miami, KS	2	2.5%
	Saline, KS	2	2.5%
	Bates, MO	2	2.5%
	Carroll, AR	2	2.5%
	Bourbon, KS	1	1.3%
	Clark, KS	1	1.3%
	Cloud, KS	1	1.3%
	Crawford, KS	1	1.3%
	Ford, KS	1	1.3%
	Nemaha, KS	1	1.3%
	Neosho, KS	1	1.3%
	Phillips, KS	1	1.3%
	Pottawatomie, KS	1	1.3%
	Buchanan, MO	1	1.3%
	Greene, MO	1	1.3%
	Harrison, MO	1	1.3%
	Henry, MO	1	1.3%
	Jasper, MO	1	1.3%
	Ray, MO	1	1.3%
	Vernon, MO	1	1.3%
Oklahoma, OK	1	1.3%	
Tulsa, OK	1	1.3%	
Outside Primary Service Area Total		80	28.4%
Grand Total		282	100.0%

*Primary Service Areas includes Clay, Jackson, Platte Counties, MO; and Johnson, Leavenworth, and Wyandotte Counties, KS.

- Since opening last January, numerous pharmaceutical company clients and other collaborators have visited the facility to monitor studies, discuss potential new studies, conduct pre-study site visits and study initiation visits, or to simply see the new facility. These are listed below including local and out of town visitors.

Month of Visit	Pharmaceutical Industry and Other Visitors to the Oncology Clinical Research Office	Local Visitors	Out of Town Visitors
January 2012	Celgene, Roche, Abbott, Crititech, ArQule, Ono, BMS, Cougar, Millennium, Exelixis, Pfizer, Lilly, Novartis, Otsuka, Genentech, Onconova, Myriad, BioVex, U of Missouri	38	31
February 2012	Celgene, BioVex, Crititech, Exelixis, Ozmosis (Toronto, Canada), Millennium, Genentech, Glaxo Smith Kline, Fresenius, Lilly, Quintiles, Pfizer, Roche, BMT CTN, Roche, Novartis, OSI Pharma, BMS	32	21
March 2012	Ono, Roche, Spectrum, Exelixis, ArQule, BioVex, Celgene, Pfizer, Deciphera, Astellas, NW Biotherapeutics, Lilly, BMS, Millennium, Novartis	27	21
April 2012	Abbott, Exelixis, Eisai, Celgene, Abbott, Millennium, Cougar, Crititech, Genentech, Novartis, Lilly, Pfizer, Roche, Seattle Genetics, BMS, Onconova, BioVex, Ono, Astellas, Amgen	42	31
May 2012	OSI, Novartis, Celgene, Fresenius, Astellas, Pfizer, Lilly, ArQule, Ozmosis, U of Chicago, Sanofi-Aventis, Millennium, Onconova, Genentech, Roche, Novartis, Exelixis, U of Colorado	29	21
June 2012	Novartis, EMB Statistical Solutions, Lilly, Crititech, Ono, BMT CTN, Merck, Genentech, BioMed Valley, Otsuka, University of Michigan, Astellas, Roche, BioVex, Genentech, Millennium, Pfizer	30	17
July 2012	Boehringer Ingelheim, Onconova, Eli Lilly, Novartis, Gynecological Oncology Group, Pfizer, Exelixis, Fresenius, Cougar, Lilly, Millennium, BioVex, Roche, Abbott, Dendreon	36	22
August 2012	Genentech, Eisai, Argos, Celgene, Sanofi-Aventis, Fresenius, Prometheus, Lilly, Novartis, Incyte, Dompe, US Oncology, OSI Pharmaceuticals, NewLinks Genetics, Aveo, Millennium, QPS	29	26
September 2012	BioVex, BMS, Onconova, Astellas, Amgen, Roche, Millennium, Novartis, Sanofi-Aventis, Celgene, Lilly, Genentech, Ozmosis, Exelixis, Seattle Genetics, Ariad, QPS	27	22
October 2012	Onconova, Sanofi-Aventis, Cougar, Novartis, Abbott, Astellas, Celetor, Celgene, Crititech, Pfizer, Roche, Incyte, BMS, Eisai, Millennium, ArQule, Quintiles, Lilly, MD Anderson, AVEO, Genentech	16	29
November 2012	ArQule, Lilly, Sanofi-Aventis, Fresenius, Beckloff, BioVex, Onconova, Novartis, OSI, Imclone, Roche, Millennium, NewLinks Genetics, BMS, Crititech, Quintiles, Onyx, Local Investors, Astellas	13	24
December 2012	Astellas, Exelixis, Pfizer, Altor, ArQule, Onconova, Novartis, Quintiles, Oncopeptides, Bayer, Lilly, Millennium, Celgene, Fresenius, AVEO, Seattle Genetics, Genentech	11	29
Total:		330	294

New local collaboration discussions within the **Early Phase Oncology Program**, the **Clinical Pharmacology Program**, and the **Frontiers Program** have been held or are underway with Children's Mercy Hospital, Quintiles, PRA, Xenotech, EMB Statistical Solutions, and QPS, LLC. Additional collaboration discussions have been held or are underway with the University of Missouri Columbia, the University of Massachusetts, the University of Colorado, the University of Michigan, Vanderbilt University, Washington University, the University of Kentucky, and the University of Iowa.

Recent events held at the CRC include:

- **14 Nov 2012** - Quarterly Meeting of the Kansas City Cancer Coalition. Tour of CRC and meeting following. This group consists of Kansas City's community cancer partners, i.e., American Cancer Society, Komen, Cancer Action, Turning Point, Young Survivor coalition, YMCA, Leukemia & Lymphoma Society, Gilda's, among others.
- **4 Dec 2012** – Winter Educational Event of the Association of Clinical Research Professionals. Focused topic was "Rural Clinical Trials: Industry sponsorship, patient studies, perception of research in rural Kansas," featuring Michael Kennedy, M.D., FAAFP, KUMC Associate Dean for Rural Health Education.
- **5 Dec 2012** – Biannual Meeting of the KU Endowment Advancement Board. Tour of CRC and reception following. The purpose of this advisory group is to advance the interests of the academic medical center and to develop community and political support and bolster philanthropic efforts for education, research, and patient care.
- **18 Jan 2013** – Greater KC Chamber: Kansas State Affairs Committee featuring a special presentation by Dave Trabert, president of the Kansas Policy Institute.

Upcoming events at the CRC include:

- *6 Feb 2013* – NE Johnson County Chamber Meeting
- *15 Feb 2013* – Greater KC Chamber: Kansas State Affairs Committee
- *15 Mar 2013* – Greater KC Chamber: Kansas State Affairs Committee
- *19 Apr 2013* – Greater KC Chamber: Kansas State Affairs Committee

Respectfully submitted:

Maxine Stoltz, PhD
Senior Executive Director
University of Kansas Clinical Research Center

Clinical Research Center
 JCERTA Budget Projections
 1/10/2012

	Approved FY13 Budget	Revised FY 13 Budget			Preliminary FY14 Budget		
		JCERT	Clinical Trial Collection	Total Revised FY13 Budget	JCERT	Clinical Trial Collection	Total Preliminary FY14 Budget
Sources of Funds							
JCERT - Balance Carry Forward	650,000	2,246,111	-	2,246,111	2,613,986	-	2,613,986
Clinical Trial Collection - Balance Carry Forward	117,065	-	-	-	-	-	-
JCERT Tax Revenue - Operating	5,000,000	5,000,000	-	5,000,000	5,000,000	-	5,000,000
Clinical Trial Collection	297,858	-	260,376	260,376	-	343,684	343,684
One-time credit (interest on construction funds)	-	247,000	-	247,000	-	-	-
Total Revenue	5,297,858	5,247,000	260,376	5,507,376	5,000,000	343,684	5,343,684
Total Sources of Funds	6,064,923	7,493,111	260,376	7,753,487	7,613,986	343,684	7,957,670
Expenditures							
Perez's salary & startup	205,026	324,207	-	324,207	212,947	-	212,947
2 Physician Positions	498,736	35,750	-	35,750	232,180	-	232,180
Research Leadership	235,536	234,596	-	234,596	324,692	-	324,692
Research Scientists	358,690	332,800	-	332,800	388,648	-	388,648
Research Laboratory Staff	161,933	138,008	-	138,008	139,388	-	139,388
Research Nursing & Study Coordination	552,321	235,070	260,376	495,446	241,216	343,684	584,900
Research Administrative Support	148,200	167,700	-	167,700	169,377	-	169,377
Subtotal CRC - Salary	2,160,441	1,468,131	260,376	1,728,506	1,708,448	343,684	2,052,132
CRC - OOE	87,000	165,000	-	165,000	125,700	-	125,700
CRC - Telephone & Networking	44,772	30,000	-	30,000	30,000	-	30,000
Mass Spec Lease	175,000	160,963	-	160,963	160,963	-	160,963
CRC Operations	2,467,214	1,824,094	260,376	2,084,469	2,025,111	343,684	2,368,795
KUH Clinical Services Settlement Cost	1,250,000	1,200,000	-	1,200,000	1,200,000	-	1,200,000
Facility Costs							
Operating Costs	802,709	802,709	-	802,709	850,000	-	850,000
Debt Service (net of BABS subsidy)	1,043,228	1,052,322	-	1,052,322	1,052,322	-	1,052,322
Facility Costs	1,845,937	1,855,031	-	1,855,031	1,902,322	-	1,902,322
Total CRC Operations	\$ 5,563,151	\$ 4,879,125	\$ 260,376	\$ 5,139,501	\$ 5,127,433	\$ 343,684	\$ 5,471,117
Annual Profit/(Loss)	(265,293)	367,875	-	367,875	(127,433)	-	(127,433)
Ending Cash Balance	501,772	2,613,986	-	2,613,986	2,486,554	-	2,486,554

K-STATE OLATHE

**Kansas State University Olathe
Campus Update
January 28, 2013**

Academic and Research Programs

Hires

- **Assistant Professor in Horticulture**, whose work focuses on food preservation and safety. She will teach in the Urban Food Systems program, conduct research and collaborate with the Horticulture center in Olathe, the food science program and extension. Start date is in February.
- **Assistant Professor, Food Science, Safety & Quality** position has been offered. Start date this summer with first priority to set up a research program.
- A search is underway for the first of two faculty positions in **Bio-Ag Engineering**; expected to be filled this summer, with classes also beginning this fall.
- **Project Coordinator** for the **Urban Water Institute** (offer to be extended in next 2 weeks following interviews last week). This position will help accelerate the development of the Institute here in Olathe.

Academic Programs

- **Emphasis in Animal Health** for the **Master's of Veterinary Biomedical Science** is expected to be approved this spring, with anticipation of courses beginning Fall 2013 or Spring 2014.
- **Master's in Adult Education** is offering five classes in Olathe this spring. A second cohort of students in the program began this January, bringing the total number of students in the program to 62.
- **Master's in Horticulture with an emphasis in Urban Food Systems** classes will begin Fall 2013.
- **Master's in Food Science** classes will begin Fall 2013.
- Students are being admitted into the **PhD in Adult Education** program.

Research

The **U.S.-China Center** is expanding into a second laboratory and will be performing contract research for companies evaluating potential animal health technologies. They are also creating a partnership with a Chinese animal health company that will occupy an office at K-State Olathe.

Outreach

K-State Olathe is hosting the February 7 "Corridor Conversation" for the KC Animal Health Corridor, featuring Dr. Jim Riviere. Dr. Riviere is the Burroughs Wellcome Fund Distinguished Professor of Pharmacology and the director of the Center for Chemical Toxicology Research and Pharmacokinetics at K-State, and will discuss the results of an Institute of Medicine study, which he chaired, examining gaps in regulatory systems of developing countries related to global drug and food safety.

The College of Engineering and the College of Business have both presented professional development programs for area professionals and are planning for additional programming in 2013.

K-12 programs this spring feature lecture series in Physics, Life Science and Veterinary Medicine.

K-State Olathe is hosting the regional Afterschool Alliance conference on February 23, a joint effort between Kansas Enrichment Network, Kansas State University Olathe, the University of Kansas, One Health Kansas, Johnson County Park & Recreation District and the YMCA of Greater Kansas City.

Highlights

The Olathe campus portion of the Kansas State 2025 Strategic plan has been completed and is posted at <http://www.k-state.edu/2025/initiatives/kstate-olathe/>. This reflects the work of a planning committee that worked throughout 2012 to articulate a strategic vision/plan for the campus and to integrate it into the larger University plan, which is available at <http://www.k-state.edu/2025/>

Dan Richardson, CEO of the Olathe Campus announced his retirement to be effective in June. Dan reduced to half-time Jan. 22 and continues to lead the campus until his successor begins this summer. A search committee has been formed and a search firm is being engaged to begin a national search.

The Olathe Campus was recently recognized as the 2012 Corporate Citizen of the Year by the Olathe Chamber of Commerce. The award recognizes dedicated service to the Olathe Chamber of Commerce and the Olathe community.

K-State Olathe will be part of the University-wide open house on April 20. A full day of activities is planned, free and open to the community, and also includes Johnson County Research and Extension (and surrounding counties) and the Olathe Horticulture Center. The Olathe campus is also participating in the university's 150th anniversary events, beginning February 14 in Manhattan, and extending through October of this year. Many of this campus's events this year will be themed around the 150th anniversary of the university.

KU EDWARDS

University of Kansas Edwards Campus – JCERT program proposals

January 2013

Masters of Engineering in Project Management, Master of Science in Project Management

Status: The full proposal is in the middle of their 4-month Board of Regents (BOR) approval process. After Dean Heilke and Diana Marrs met with the PSM organization, it was determined that the proposed PSM degree would be more appropriately titled “MS in Proj Mgmt”. The Masters of Engineering degree is for engineers and the other is for other professionals (business, science). April is the expected approval date.

Professional Science Masters in Environmental Assessment

Status: The proposal has passed through the College of Liberal Arts and Sciences (CLAS) approval process and goes to the BOR in February. May is earliest possible approval date. We are also applying for official PSM affiliation for this degree (a national standard of quality).

MS in Educational Technology

Status: Funding needed for this degree has been approved by university. Confirmation letter sent to School of Education (SOE) on November 19th. Launch anticipated fall 2013 or spring 2014. This will be determined after meeting with SOE in early February to discuss next steps.

BS in Exercise Science

Status: Funding needed for this degree has been approved by university. Confirmation letter sent to SOE on November 19th. This proposal has been sent to the BOR and will have its first review in January 2013. Anticipated approval April 2013. Launch anticipated fall 2013 or spring 2014. This will be determined after meeting with SOE early February to discuss next steps.

BS in Graphic Design

Status: Johnson County Community College (JCCC) and Lois Greene (KU Lawrence) met in December. Another meeting will occur in January or early February to continue to work out curriculum details.

PSM in Biotechnology - (on hold until the BAS degree below has been completed)

BAS Biotechnology

Status: The Executive summary has passed CLAS approval and has been submitted to the Provost office and will soon go out for Dean’s two-week review. (Next step will be to make revisions as needed and complete the full proposal documentation for the BOR.)

Current JCERT program enrollments;

Bachelor of Business Administration (BBA); **133** students total as of spring 2013

Bachelor of Science in Information Technology (BSIT); **10** students total as of spring 2013

KU Edwards Campus
 JCERTA Budget Projections
 1/17/2013

	Approved FY13 Budget	Projected FY 13 Budget			Preliminary FY 14 Budget		
		JCERT	Tuition Revenue	Total Projected FY13 Budget	JCERT	Tuition Revenue	Total Projected FY14 Budget
Sources of Funds							
JCERT - Balance Carry Forward	3,423,406	3,753,538		3,753,538	3,988,486		3,988,486
JCERT Sales Tax Revenue	5,000,000	5,000,000		5,000,000	5,000,000		5,000,000
Misc. Income--Interest	-	10,508		10,508	-		-
Tuition Revenue	561,461		491,458	491,458		754,961	754,961
Total Revenue	5,561,461	5,010,508	491,458	5,501,966	5,000,000	754,961	5,754,961
Total Sources of Funds	8,984,867	8,764,046	491,458	9,255,504	8,988,486	754,961	9,743,447
Student Services/PR/Recruitment							
Scholarships	50,000	50,000		50,000	50,000		50,000
Salaries and Fringes	652,059	652,059		652,059	718,171		718,171
Public Relations	193,500	193,500		193,500	160,000		160,000
Recruitment	62,000	55,000		55,000	130,000		130,000
Library	24,623	24,623		24,623	24,623		24,623
Administration and Travel	146,000	140,000		140,000	146,000		146,000
Subtotal Student Services/PR/Recruitment	1,128,182	1,115,182		1,115,182	1,228,794		1,228,794
Programmatic Costs							
BBA	1,445,766	997,080	486,031	1,483,111	1,196,496	538,423	1,734,919
BSIT	401,625	250,000	5,428	255,428	393,350	98,338	491,688
PSM	99,750	50,000	-	50,000	272,800	68,200	341,000
Future programs	62,500	20,000	-	20,000	200,000	50,000	250,000
Subtotal Programmatic Costs	2,009,641	1,317,080	491,459	1,808,539	2,062,646	754,961	2,817,607
Facility Costs							
Building Maintenance	20,000	20,000		20,000	20,000		20,000
Communications	42,000	42,000		42,000	42,000		42,000
Custodial Service	58,000	58,000		58,000	58,000		58,000
Debt Service on Bonds	1,980,580	1,980,580		1,980,580	1,981,080		1,981,080
Security	35,910	35,910		35,910	36,987		36,987
Technology	40,000	40,000		40,000	40,000		40,000
Utilities	167,000	160,000		160,000	167,000		167,000
Building Construction	-	6,808		6,808	-		-
Subtotal Facility Costs	2,343,490	2,343,298		2,343,298	2,345,067		2,345,067
Total Operations	5,481,313	4,775,560	491,459	5,267,019	5,636,507	754,961	6,391,468
Annual Profit/(Loss)	80,148	234,948	(0)	234,948	(636,507)	-	(636,507)
Ending Cash Balance	3,503,554	3,988,486	(0)	3,988,486	3,351,979	-	3,351,979